Clinical Trials Logo

Filter by:
NCT ID: NCT02009579 Active, not recruiting - Clinical trials for Uterine Cervical Neoplasms

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Start date: March 2014
Phase: Phase 2
Study type: Interventional

Indication: Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed. Study design: This is a phase II randomized, double blind and placebo controlled trial evaluating the efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel followed by Nintedanib/placebo maintenance in the treatment of patients with advanced or recurrent cervical cancer. A total of 120 patients will be randomized between the experimental and control arm in a 1:1 ratio. Randomization will be stratified for 1previous chemotherapy for metastatic disease (yes/no) and 2disease status (Stage IVB primary versus recurrent disease). Experimental arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks. Control arm: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks. Subjects without evidence of disease progression after completion or discontinuation of the study treatment will be followed until radiographic disease progression, withdrawal of consent or death.

NCT ID: NCT02007512 Active, not recruiting - Breast Cancer Clinical Trials

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Start date: December 13, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast cancer.

NCT ID: NCT02003924 Active, not recruiting - Prostate Cancer Clinical Trials

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

PROSPER
Start date: October 31, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.

NCT ID: NCT01994798 Active, not recruiting - Clinical trials for Peripheral (Lowr Extremity) Arterial Disease.

Rapid Exchange Devices Observational Registry.

RXRegistry
Start date: November 2013
Phase: N/A
Study type: Observational [Patient Registry]

This registry is designed to assess the clinically relevant benefits of balloon angioplasty and stenting in superficial femoral and popliteal artery, using rapid exchange technology.

NCT ID: NCT01985659 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Nodal Upstaging in VATS Anatomical Resections for NSCLC

Start date: November 2013
Phase: N/A
Study type: Observational

This study investigates peropeative nodal upstaging during anatomical resections for non-small-cell-lung-cancer in an era of rising numbers of VATS anatomical resections. In case of comparable study groups, unchanged pretreatment staging and equal quality of pathologic examination, lymph node upstaging is a marker of surgical quality and can be used to study the quality of a new surgical technique.

NCT ID: NCT01969578 Active, not recruiting - Clinical trials for Salivary Gland Cancer

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Start date: September 24, 2015
Phase: Phase 2
Study type: Interventional

Salivary Gland (SG) Cancers are a rare and heterogeneous group of tumors, usually approached by multidisciplinary teams in high specialized centers. Until today no standard of care exists to treat these cancers. The identification of a target, the androgen receptor, in SG tumors has allowed for new treatment strategies options for this rare group of diseases. As a matter of fact, strong positivity for androgen expression has been found in salivary duct carcinoma and adenocarcinomas. The purpose of this study is therefore to evaluate the efficacy and safety of chemotherapy versus androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic AR expressing SGCs. The study will include two cohorts of patients: Cohort A, which comprises chemo-naïve patients, and Cohort B, which comprises pretreated patients.

NCT ID: NCT01965899 Active, not recruiting - Syncope Clinical Trials

Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System

Start date: September 2013
Phase: N/A
Study type: Interventional

The purpose of the Reveal LINQ Usability Study is to assess the functionality of the Reveal LINQ insertable cardiac monitor and accompanying system in patients indicated for an insertable cardiac monitor

NCT ID: NCT01960504 Active, not recruiting - Clinical trials for Coronary Artery Disease

First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

BIOSOLVE-II
Start date: October 2013
Phase: N/A
Study type: Interventional

BIOSOLVE-II is a prospective, international, multicenter, First in Man study. The purpose of this study is to assess the safety and clinical performance of the drug eluting absorbable metal scaffold (DREAMS 2nd Generation).

NCT ID: NCT01959906 Active, not recruiting - Esophageal Cancer Clinical Trials

Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.

Start date: July 2013
Phase: N/A
Study type: Observational

A suspicious circumferential resection margin (CRM), defined as tumor cells within 1 mm of the CRM, is still controversial. The aim of this study was to compare the clinical significance of a suspicious CRM to histologically positive (R1) and negative margin (R0) resections in patients with pT3 esophageal and GE-Junction tumors.

NCT ID: NCT01958710 Active, not recruiting - Clinical trials for Pulmonary Fungal Diseases

Outcome After Treatment of Pulmonary Aspergilloma

Start date: October 2013
Phase: N/A
Study type: Observational

Retrospective analysis of surgery and/or bronchial embolisation for pulmonary aspergilloma.